Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $46.90.

Several equities research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Guggenheim began coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price objective on the stock. Bank of America boosted their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. JonesTrading started coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th.

Tyra Biosciences Price Performance

Shares of TYRA opened at $26.25 on Thursday. The firm has a market capitalization of $1.57 billion, a P/E ratio of -10.94 and a beta of 0.77. Tyra Biosciences has a one year low of $9.96 and a one year high of $40.65. The business has a fifty day moving average of $29.96 and a 200 day moving average of $32.66.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Analysts expect that Tyra Biosciences will post -2.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently bought and sold shares of TYRA. Jennison Associates LLC bought a new position in shares of Tyra Biosciences during the 1st quarter valued at approximately $24,222,000. 5AM Venture Management LLC lifted its holdings in Tyra Biosciences by 9.6% during the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock valued at $27,060,000 after purchasing an additional 90,000 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Tyra Biosciences in the fourth quarter worth approximately $2,092,000. Fisher Asset Management LLC bought a new position in shares of Tyra Biosciences in the fourth quarter worth approximately $757,000. Finally, Strs Ohio increased its stake in shares of Tyra Biosciences by 2,485.7% in the first quarter. Strs Ohio now owns 18,100 shares of the company’s stock worth $693,000 after purchasing an additional 17,400 shares in the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.